SEARCH:   Advanced

Blood, 15 June 2007, Vol. 109, No. 12, pp. 5096-5103. Prepublished online as a Blood First Edition Paper on February 15, 2007; DOI 10.1182/blood-2006-11-055012. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-11-055012v1 109/12/5096    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Vijay, A. Articles by Gertz, M. A. Search for Related Content PubMed PubMed Citation Articles by Vijay, A. Articles by Gertz, M. A. Related Collections Neoplasia Oncogenes and Tumor Suppressors Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW IN TRANSLATIONAL HEMATOLOGY Waldenström macroglobulinemia Arun Vijay1, and Morie A. Gertz2 1 Austin Medical Center–Mayo Health System, Austin, MN; 2 Division of Hematology, Mayo Clinic, Rochester, MN In the past 36 months, new developments have occurred both in the understanding of the biology of Waldenström macroglobulinemia (WM) and in therapeutic options for WM. Here, we review the classification, clinical features, and diagnostic criteria of the disease. WM is a B-cell neoplasm characterized by lymphoplasmacytic infiltration of the bone marrow and a monoclonal immunoglobulin M (IgM) protein. The symptoms of WM are attributable to the extent of tumor infiltration and to elevated IgM levels. The most common symptom is fatigue attributable to anemia. The prognostic factors predictive of survival include the patient's age, ß2-microglobulin level, monoclonal protein level, hemoglobin concentration, and platelet count. Therapy is postponed for asymptomatic patients, and progressive anemia is the most common indication for initiation of treatment. The main therapeutic options include alkylating agents, nucleoside analogues, and rituximab. Studies involving combination chemotherapy are ongoing, and preliminary results are encouraging. No specific agent or regimen has been shown to be superior to another for treatment of WM. Novel agents such as bortezomib, perifosine, atacicept, oblimersen sodium, and tositumomab show promise as rational targeted therapy for WM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Koshiol, G. Gridley, E. A. Engels, M. L. McMaster, and O. Landgren Chronic Immune Stimulation and Subsequent Waldenstrom Macroglobulinemia Arch Intern Med, September 22, 2008; 168(17): 1903 - 1909. [Abstract] [Full Text] [PDF] S. Poulain, I. Dervite, X. Leleu, V. Coiteux, P. Duthilleul, and P. Morel The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less Haematologica, July 1, 2008; 93(7): 1109 - 1111. [Full Text] [PDF] H. T. Ngo, X. Leleu, J. Lee, X. Jia, M. Melhem, J. Runnels, A.-S. Moreau, N. Burwick, A. K. Azab, A. Roccaro, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia Blood, July 1, 2008; 112(1): 150 - 158. [Abstract] [Full Text] [PDF] X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia Blood, May 15, 2008; 111(10): 5068 - 5077. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020